Hypnosis in Internal Medecine (HypnoMedIn)

Hypnose en médecine Interne

Description of the short and long-term impact of hypnosis sessions for patient having benefited from at least one hypnosis session in internal medicine at the french hospital "Groupe Hospitalier Mutualiste de Grenoble", with the help of a qualitative survey made by phone.

Study Overview

• Status: Not yet recruiting
• Conditions: Autoimmune Diseases; Medically Unexplained Symptoms; Hypnosis
• Intervention / Treatment: Procedure: Hypnosis session

Detailed Description

The practice of hypnosis has experienced a recent boom in medicine, with a multiplication of its fields of action. Regarding internal medicine, the influence of the psyche on the immune system makes the use of hypnosis particularly relevant for autoimmune diseases. Medically unexplained symptoms (another important field of internal medicine) are also strongly psychosomatic and thus susceptible to hypnosis. The hypothesis is thus made that hypnosis can bring multiple benefits to internal medicine patients.

The main objective of this study is to describe the short and long-term impact of hypnosis sessions for patient having benefited from at least one hypnosis session in internal medicine at the french hospital "Groupe Hospitalier Mutualiste de Grenoble", with the help of a qualitative survey made by phone.

Moreover retrospective medical data concerning these patients will be collected to determine their medical history, their main symptoms et reasons to use hypnosis.

• Study Type: Observational
• Enrollment (Anticipated): 70

Contacts and Locations

• Study Contact: Name: Maxime LUGOSI, PhD; Phone Number: 04 76 76 37 07; Email: mlugosi@chu-grenoble.fr
• Study Contact Backup: Name: Mélanie ARNAUD; Email: marnaud3@chu-grenoble.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All consecutive patients who had at least one hypnosis session in internal medicine at the hospital "Groupe Hospitalier Mutualiste de Grenoble" between 08/28/2015 (date of the very first hypnosis consultation in internal medicine) and 03/17/2020 (date of confinement due to Covid19 in France)

Description

Inclusion Criteria:

• All consecutive patients who had at least one hypnosis session in internal medicine at the hospital "Groupe Hospitalier Mutualiste de Grenoble" between 08/28/2015 (date of the very first hypnosis consultation in internal medicine) and 03/17/2020 (date of confinement due to Covid19 in France)

Exclusion Criteria:

• Patient who had a hypnosis session, but who is not followed for a pathology in internal medicine or in internal medicine with a pneumological orientation

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Description of the short and long-term impact of hypnosis sessions thanks to a qualitative phone survey	Improvement in symptoms and quality of life, assessed thanks to a qualitative phone survey by 5-levels Likert scales	Assessed only once. Phone call will be performed between march 2021 and June 2021

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of the reasons for patient satisfaction / dissatisfaction	Qualitative description by an open question in the phone survey	Assessed only once. Phone call will be performed between march 2021 and June 2021
Description of the characteristics of these patients and of the hypnosis sessions	Patients'characteristics described in medical records	At inclusion

Collaborators and Investigators

• Sponsor: University Hospital, Grenoble
• Collaborators: Groupe Hospitalier Mutualiste de Grenoble
• Investigators: Principal Investigator: Maxime LUGOSI, PhD, Chu Grenoble Alpes

Publications and helpful links

General Publications

• Lugosi M, Sacre K, Lidove O, Chauveheid MP, Brihaye B, Laissy JP, Chauchard M, Papo T. [Long-term follow-up of a French cohort of retroperitoneal fibrosis]. Rev Med Interne. 2013 Oct;34(10):591-9. doi: 10.1016/j.revmed.2013.02.002. Epub 2013 Mar 14. French.
• Lugosi M, Alberti C, Zahar JR, Garrouste M, Lemiale V, Descorps-Desclere A, Ricard JD, Goldgran-Toledano D, Cohen Y, Schwebel C, Vesin A, Timsit JF, Azoulay E. Aspergillus in the lower respiratory tract of immunocompetent critically ill patients. J Infect. 2014 Sep;69(3):284-92. doi: 10.1016/j.jinf.2014.04.010. Epub 2014 Jun 9.
• Tolsma V, Schwebel C, Azoulay E, Darmon M, Souweine B, Vesin A, Goldgran-Toledano D, Lugosi M, Jamali S, Cheval C, Adrie C, Kallel H, Descorps-Declere A, Garrouste-Orgeas M, Bouadma L, Timsit JF. Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile. Chest. 2014 Nov;146(5):1205-1213. doi: 10.1378/chest.13-2618.
• Gunther SC, Schwebel C, Hamidfar-Roy R, Bonadona A, Lugosi M, Ara-Somohano C, Minet C, Potton L, Cartier JC, Vesin A, Chautemps M, Styfalova L, Ruckly S, Timsit JF. Complications of intravascular catheters in ICU: definitions, incidence and severity. A randomized controlled trial comparing usual transparent dressings versus new-generation dressings (the ADVANCED study). Intensive Care Med. 2016 Nov;42(11):1753-1765. doi: 10.1007/s00134-016-4582-2. Epub 2016 Oct 12.

Study record dates

Study Major Dates

• Study Start (Anticipated): June 1, 2021
• Primary Completion (Anticipated): July 1, 2021
• Study Completion (Anticipated): October 1, 2021

Study Registration Dates

• First Submitted: January 4, 2021
• First Submitted That Met QC Criteria: January 4, 2021
• First Posted (Actual): January 7, 2021

Study Record Updates

• Last Update Posted (Actual): May 5, 2021
• Last Update Submitted That Met QC Criteria: May 4, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Keywords: survey; internal medicine; qualitative; impact of hypnosis
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Medically Unexplained Symptoms
• Other Study ID Numbers: 2020-A03469-30

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No